基因编辑公司Intellia Therapeutics(NTLA)今日盘前股价大跌5.06%,引起了市场的广泛关注。分析人士认为,投行下调该公司投资评级成为主要原因。
据报道,投资银行摩根士丹利将Intellia Therapeutics的评级由"增持"下调至"中性",目标股价也由45美元大幅下调至13美元。另一家投资银行摩根大通也将该公司的投资评级从"增持"下调至"中性"。
分析师普遍对该公司的发展前景看空,导致下调评级和目标价。这直接打击了市场对Intellia的信心,推动了公司股价在今日盘前大幅下跌。作为一家从事基因编辑技术研发和应用的科技公司,Intellia目前仍处于培育期,产品线有待丰富。未来能否顺利进入商业化阶段仍存在不确定性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.